Prestige Consumer Healthcare Inc. (PBH) Stock Price & Analysis
Prestige Consumer Healthcare Inc. (PBH) rose 1.97% to USD 48.66 as of June 10, 2026 at 04:03 UTC, according to Nexqual real-time market data.
PBH last closed at USD 47.72; the session ranged USD 48.16–49.81 on volume of 632,477 shares. Market capitalization is $2.31B, with a 52-week range of USD 42.62–87.12 (NYQ). Source: Nexqual, June 10, 2026 at 04:03 UTC.
Key Statistics (as of June 10, 2026 at 04:03 UTC)
| Price | USD 48.66 |
|---|---|
| Change | ▲ 1.97% (up) |
| Previous Close | USD 47.72 |
| Open | USD 47.92 |
| Day Range | USD 48.16 – 49.81 |
| 52-Week Range | USD 42.62 – 87.12 |
| Volume | 632,477 shares |
| Market Cap | $2.31B |
| Exchange | NYQ |
Technical Analysis (PBH)
Nexqual's technical model rates PBH "SELL" based on 1 bullish and 4 bearish signals across 123 daily candles, as of June 10, 2026 at 04:03 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 41.22 (neutral) |
| vs SMA50 | Below (USD 53.04) |
| MACD | -2.04 (negative) |
Analyst Ratings (PBH)
Wall Street analysts rate PBH "Buy" based on 5 analysts, with a mean price target of USD 66.8 (range USD 50–75), per Nexqual as of June 10, 2026 at 04:03 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 66.8 |
| High Target | USD 75 |
| Low Target | USD 50 |
| Buy / Hold / Sell | 5 / 2 / 0 |
Earnings (PBH)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD 0.87 |
| Revenue Estimate | $250.11M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 1.23 vs est 1.39 ▼ miss |
| 2025-12-31 | USD 1.14 vs est 1.16 ▼ miss |
| 2025-09-30 | USD 0.86 vs est 0.97 ▼ miss |
| 2025-06-30 | USD 0.95 vs est 0.99 ▼ miss |
Source: Nexqual, June 10, 2026 at 04:03 UTC.
Financials & Fundamentals (PBH)
| Total Revenue | $1.09B |
|---|---|
| Revenue Growth (YoY) | -5.00% |
| Gross Margin | +55.65% |
| Operating Margin | +26.81% |
| Profit Margin | +17.48% |
| ROE | +10.22% |
| Debt / Equity | 55.39 |
| Current Ratio | 3.57 |
| Total Cash | $63.87M |
| Total Debt | $1.05B |
| Free Cash Flow | $192.76M |
Source: Nexqual, June 10, 2026 at 04:03 UTC.
Financial Health Score (PBH)
Nexqual rates Prestige Consumer Healthcare Inc.'s overall financial health "Solid" across five dimensions, as of June 10, 2026 at 04:03 UTC.
| Growth | Weak — Revenue -4% YoY (annual), declining |
|---|---|
| Profitability | Strong — Gross margin 56%, operating 27% |
| Balance Sheet | Strong — $64M cash vs $1.05B debt |
| Cash Flow | Strong — FCF $193M, 18% margin |
| Efficiency | Mixed — ROE 10%, ROA 5.6% |
Ownership (PBH)
| Insider Ownership | +1.41% |
|---|---|
| Institutional Ownership | +113.43% |
| Shares Outstanding | 47.37M |
| Float | 46.76M |
| Short % of Float | +7.38% |
Source: Nexqual, June 10, 2026 at 04:03 UTC.
Leadership (PBH)
Prestige Consumer Healthcare Inc. is led by Ronald M. Lombardi (age 61), Chairman, President & CEO, per Nexqual as of June 10, 2026 at 04:03 UTC.
| Chairman, President & CEO | Ronald M. Lombardi (age 61) |
|---|---|
| CFO & COO | Christine Sacco (age 49) |
| Executive Vice President of Marketing & Sales | Adel Mekhail (age 63) |
| Senior Vice President of Operations | Jeffrey Zerillo (age 63) |
| Director of Investor Relations | Philip David Terpolilli C.F.A. |
Major Backers & Investors (PBH)
Notable institutional backers of Prestige Consumer Healthcare Inc. include Ariel Investments, LLC, Kayne Anderson Rudnick Investment Management LLC, Allspring Global Investments Holdings, LLC, according to Nexqual as of June 10, 2026 at 04:03 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Ariel Investments, LLC | 9.02% |
| Kayne Anderson Rudnick Investment Management LLC | 4.65% |
| Allspring Global Investments Holdings, LLC | 3.29% |
| Morgan Stanley | 2.87% |
| Ariel Investment Trust-Ariel Fund | 2.67% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 24.07% |
| Vanguard Group | 18.36% |
| Dimensional Fund Advisors | 5.64% |
| State Street | 4.16% |
| Geode Capital | 3.08% |
Source: Nexqual, June 10, 2026 at 04:03 UTC.
From Prestige Consumer Healthcare Inc.'s Latest SEC 10-K Filing (filed 2026-05-14)
Key Strengths & Strategy (as disclosed to the SEC)
- During 2026, 2025 and 2024, Amazon accounted for approximately 15%, 14%, and 11%, respectively, of our gross revenues. 6 We expect that for future periods a significant portion of our net sales will continue to be derived from a small number of customers, including Walmart and Amazon.
- We believe our business model allows us to integrate acquisitions in an efficient manner, while also providing opportunities to realize significant cost savings.
- Our primary contract manufacturers provide comprehensive services from product development through the manufacturing of finished goods.  This approach results in minimal capital expenditures and maximizes our cash flow, which allows us to reinvest to support our marketing initiatives, fund brand acquisitions and repay outstanding indebtedness.
Partnerships
- Although we are continually in the process of negotiating long-term contracts with certain key manufacturers, we may not be able to reach a timely agreement.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ITGR | Integer Holdings Corporation | USD 94.1 | ▲ 2.3% |
| MD | Pediatrix Medical Group, Inc. | USD 23.66 | ▲ 4.64% |
| KFY | Korn Ferry | USD 73.76 | ▲ 1.99% |
| SEM | Select Medical Holdings Corpora | USD 16.63 | ▲ 0.54% |
| USPH | U.S. Physical Therapy, Inc. | USD 61.8 | ▼ 2.6% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 04:03 UTC. This page is informational and not investment advice.